1. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Issue 17 (13th June 2014) Authors: Kaufman, Peter A.; Bloom, Kenneth J.; Burris, Howard; Gralow, Julie R.; Mayer, Musa; Pegram, Mark; Rugo, Hope S.; Swain, Sandra M.; Yardley, Denise A.; Chau, Miu; Lalla, Deepa; Yoo, Bongin; Brammer, Melissa G.; Vogel, Charles L. Journal: Cancer Issue: Volume 120:Issue 17(2014) Page Start: 2657 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Issue 17 (13th June 2014) Authors: Kaufman, Peter A.; Bloom, Kenneth J.; Burris, Howard; Gralow, Julie R.; Mayer, Musa; Pegram, Mark; Rugo, Hope S.; Swain, Sandra M.; Yardley, Denise A.; Chau, Miu; Lalla, Deepa; Yoo, Bongin; Brammer, Melissa G.; Vogel, Charles L. Journal: Cancer Issue: Volume 120:Issue 17(2014) Page Start: 2657 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status. Issue 17 (17th June 2013) Authors: Garrison, Louis P.; Lalla, Deepa; Brammer, Melissa; Babigumira, Joseph B.; Wang, Bruce; Perez, Edith A. Journal: Cancer Issue: Volume 119:Issue 17(2013) Page Start: 3113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status. Issue 17 (17th June 2013) Authors: Garrison, Louis P.; Lalla, Deepa; Brammer, Melissa; Babigumira, Joseph B.; Wang, Bruce; Perez, Edith A. Journal: Cancer Issue: Volume 119:Issue 17(2013) Page Start: 3113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer. (9th April 2012) Authors: Danese, Mark D.; Lindquist, Karla; Doan, Justin; Lalla, Deepa; Brammer, Melissa; Griffiths, Robert I. Other Names: Fryzek Jon Academic Editor. Journal: Journal of cancer epidemiology Issue: Volume 2012(2012) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Health‐Related Quality of Life With Adjuvant Docetaxel‐ and Trastuzumab‐Based Regimens in Patients with Node‐Positive and High‐Risk Node‐Negative, HER2‐Positive Early Breast Cancer: Results from the BCIRG 006 Study. (28th June 2013) Authors: Au, Heather‐Jane; Eiermann, Wolfgang; Robert, Nicholas J.; Pieńkowski, Tadeusz; Crown, John; Martin, Miguel; Pawlicki, Marek; Chan, Arlene; Mackey, John; Glaspy, John; Pintér, Tamás; Liu, Mei‐Ching; Fornander, Tommy; Sehdev, Sandeep; Ferrero, Jean‐Marc; Bée, Valerie; Santana, Maria J.; Miller, Da... Journal: Oncologist Issue: Volume 18:Number 7(2013) Page Start: 812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting. (1st August 2014) Authors: Hurvitz, Sara; Guerin, Annie; Brammer, Melissa; Guardino, Ellie; Zhou, Zheng-Yi; Latremouille Viau, Dominick; Wu, Eric Q.; Lalla, Deepa Journal: Oncologist Issue: Volume 19:Number 9(2014) Page Start: 901 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Investigation of Adverse‐Event‐Related Costs for Patients With Metastatic Breast Cancer in a Real‐World Setting. (1st August 2014) Authors: Hurvitz, Sara; Guerin, Annie; Brammer, Melissa; Guardino, Ellie; Zhou, Zheng‐Yi; Latremouille Viau, Dominick; Wu, Eric Q.; Lalla, Deepa Journal: Oncologist Issue: Volume 19:Number 9(2014) Page Start: 901 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer. Issue 5 (12th November 2013) Authors: Welslau, Manfred; Diéras, Veronique; Sohn, Joo‐Hyuk; Hurvitz, Sara A.; Lalla, Deepa; Fang, Liang; Althaus, Betsy; Guardino, Ellie; Miles, David Journal: Cancer Issue: Volume 120:Issue 5(2014) Page Start: 642 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer. Issue 5 (12th November 2013) Authors: Welslau, Manfred; Diéras, Veronique; Sohn, Joo‐Hyuk; Hurvitz, Sara A.; Lalla, Deepa; Fang, Liang; Althaus, Betsy; Guardino, Ellie; Miles, David Journal: Cancer Issue: Volume 120:Issue 5(2014) Page Start: 642 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗